Drug Profile
Apomorphine - Innotesto
Alternative Names: AporonLatest Information Update: 05 Feb 2021
Price :
$50
*
At a glance
- Originator INNOTESTO bvba
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Parkinson's disease
Most Recent Events
- 29 Dec 2020 Chemical structure information added
- 10 Nov 2020 Phase-I/II clinical trials in Parkinson's disease (In adults, In the elderly) in Netherlands (Buccal) (EudraCT2019-003315-60)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in Belgium